Compare New York Times Co (NYT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Regeneron Pharmaceuticals Inc — how do they compare? New York Times Co trades at $64.72 (market cap $10.45B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.42%). Which is the better fit depends on your goals.
| NYT | REGN | |
|---|---|---|
Market Cap | $10.45B | $83.19B |
Sector | Media | Health |
52-Week High | $85.86 | $812.27 |
52-Week Low | $54.66 | $555.51 |
Enterprise Value | $9.85B | $77.90B |
Dividend Yield | 1.42% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times (NYT) stock trades at $63.54, down 1.9% recently, with a bearish technical signal from moving averages but neutral oscillators. Fundamentally, the company shows strong profitability with a 13.19% net income margin and consistent earnings beats, including Q2 2026 EPS of $0.69 versus $0.663 expected. Revenue growth is steady, reaching $2.82B in 2025, though digital subscriber additions have moderated, contributing to near-term stock weakness.
Outlook remains mixed; analyst consensus targets $77.50 with 29% buy ratings, but slower subscriber growth and high valuation (P/E 26.48) pose risks. Opportunities include digital expansion and pricing power, while risks involve competition and economic sensitivity. The stock's current level near support at $63 may attract value-oriented investors if fundamentals hold.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
